About

About Daxiang Biotech Daxiang Biotech is a leading innovator in organoid-on-a-chip technologies in China and a global provider of integrated microphysiological systems (MPS) solutions for drug discovery, translational research, and precision medicine. Founded in 2018, the company has established a fully integrated, end-to-end platform spanning design, modeling, R&D, manufacturing, and application of human-relevant in vitro systems. Powered by its core technology framework—Organoid-on-a-Chip + AI + Automation—Daxiang develops proprietary instruments, chips, reagents, and advanced human-relevant models to help global life sciences partners improve preclinical decision-making and accelerate development timelines. At the core of its technology is the IBAC® (Integrated Biomimetic Array Chip) platform, which integrates stem cell biology, organoid science, and microfluidics to recreate physiologically relevant human tissue environments in vitro. Based on this platform, Daxiang has developed 50+ organoid culture kits and 100+ humanized physiological and disease models across oncology, liver, gastrointestinal, kidney, brain, and cardiovascular applications. Daxiang’s technologies have been validated by third-party institutions and adopted by leading pharmaceutical companies, biotechnology companies, hospitals, and research institutes. The company has supported multiple IND-enabling programs, helping partners improve translational predictability and reduce reliance on animal models in selected applications. Daxiang Biotech is actively seeking global partnerships with pharmaceutical and biotech companies, CRO/CDMO organizations, research institutions, distributors, and strategic investors. Key collaboration interests include drug discovery services, translational model co-development, precision medicine applications, regional commercialization, and AI-enabled next-generation preclinical platforms.